In 1957 Dr. John Fletcher Prudden, a New York surgeon, came across critical new medical research undertaken by several of his colleagues at Columbia Presbyterian Hospital. They were studying the effectiveness of Bovine Tracheal Cartilage in healing massive surgical wounds, and they found that this material speeds healing by 55 percent. Despite the amazing results, they were about to abandon their research because the federal funding expired. Thus they offered the drug/material to John Prudden, and he accepted.
After changing the name of the Bovine Cartilage material to “Catrix,” Dr. Prudden spent the next forty years (1958-1998) conducting FDA-approved research on the healing properties of Catrix, which had the unique combined abilities to simultaneously act as a very effective anti-inflammatory and immunological stimulant. This was something which no previous medication had ever achieved. Furthermore there were virtually no side effects.
In 1976, Whitney Ulrich, introduced John to Jerome and Mike Rosow in the hope that they might help him better market Catrix. Whitney had experienced amazing results using Catrix to treat her previously agonizing osteoarthritis. After several months of treatment, her symptoms disappeared. At that time John was testing Catrix in various forms, including capsules, cream, suppositories, and injectable for a wide variety of medical conditions which included Cancer, Osteoarthritis, Scleroderma, Shingles, and others with great success. He also briefly tested Shark Cartilage and found similar results. Sadly, John Prudden passed away in 1998.